Pharmaceutical Executive
AbelsonTaylor
QUESTIONS?
AbelsonTaylor
BRAND Psoriatic arthritis disease awareness CLIENT Amgen/Wyeth FROM LEFT: Andy McAfee, associate creative director; James Gillespie, senior copywriter; George Starr, senior art director; Holly Wright, senior account supervisor; Eric Pernod, associate creative director, art
The goal of the "Questions" print campaign was to create awareness among psoriasis patients about joint pain, drive them to the Web site MyPsoriasisConnection.com for more information, and encourage them to talk with their dermatologist.
The PSA is aimed at educating psoriasis patients who are also experiencing joint pain about psoriatic arthritis—and the fact that they could be at risk for permanent joint damage. "The ad quickly telegraphs to patients with psoriatic plaques, 'Hey, this ad is for me,' and to start that conversation with their dermatologist," says Andy McAfee, associate creative director. "This is an important educational message for patients, so we really wanted to be sure they didn't miss it."
Nearly four in 10 people with psoriasis have psoriatic arthritis. But often these folks never make the connection between their skin condition and joint pain. While the skin symptoms are more evident, patients tend to ignore the joint pain symptomatic of psoriatic arthritis.
The headline, along with the psoriatic plaques forming the question mark on the arm, represents a single-minded way to help patients realize that the question—"Is it actually psoriatic arthritis?"—is for them.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
March 14th 2025New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.